Related Experiment Video
Updated: Oct 10, 2025
08:55
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
12.4K
CHFR and Paclitaxel Sensitivity of Ovarian Cancer
Andrea E Wahner Hendrickson1, Daniel W Visscher2, Xiaonan Hou1
1Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Cancers
|December 10, 2021
Summary
The CHFR protein
Area of Science:
- Oncology
- Molecular Biology
- Cellular Stress Response
Background:
- The poly(ADP-ribose) binding protein CHFR regulates cellular responses to mitotic stress.
- UBC13, a deubiquitinase regulating CHFR, correlates with improved survival in paclitaxel-treated ovarian cancer.
- Limited data exists on CHFR expression in ovarian cancer despite taxane use.
Purpose of the Study:
- To investigate the expression of CHFR in ovarian cancer.
- To determine the association of CHFR levels with clinicopathological features and patient outcomes.
- To assess the relationship between CHFR expression and paclitaxel sensitivity in ovarian cancer models.
Main Methods:
- Tissue microarrays of 417 ovarian carcinoma samples were stained for CHFR and scored.
- CHFR expression was analyzed against histology, grade, stage, time to progression (TTP), and overall survival (OS).
- CHFR expression and paclitaxel sensitivity were evaluated in 69 ovarian cancer patient-derived xenografts (PDXs).
Main Results:
- CHFR expression positively correlated with serous histology, higher grade, and advanced stage ovarian cancer.
- No significant association was found between CHFR staining and OS or TTP in high-grade serous ovarian cancer patients treated with platinum/taxane chemotherapy.
- CHFR expression did not correlate with paclitaxel sensitivity in ovarian cancer PDXs.
Conclusions:
- CHFR expression is linked to aggressive features in ovarian cancer but does not predict survival or paclitaxel response.
- CHFR levels are unlikely to be a major determinant of paclitaxel sensitivity in high-grade serous ovarian cancer.
